RANI (ranitherapeutics.com) Future Price to Earnings

Official company branding of Rani Therapeutics Holdings, Inc. (RANI)

Rani Therapeutics generates revenue through the implementation of innovative drug delivery systems, including the robotic RaniPill capsule. The company's forward P/E ratio history reflects risk cost dynamics, where the value of 0.00 characterizes this level. Geopolitical tensions and logistical disruptions are slowing the progress of testing. Stable management under Talat Imran ensures the precise advancement of technologies through the development stages.

Rani Therapeutics - RANI Market Cap to Future Earnings Ratio (period 07/04/2022 - 11/15/2026)

Summary analytical data breakdowns for ranitherapeutics.com (RANI)

Fundamental valuation:RANI Rani Therapeutics
Brand item of Rani Therapeutics

The forward P/E reflects the market value of the asset relative to projected net income, allowing for an assessment of the premium paid for expected business growth. By analyzing the forward P/E of Rani Therapeutics (RANI), an investor views capitalization through the lens of the efficiency of RaniPill robotic lines, where the automation of biologic encapsulation in clean rooms is expected to scale margins and reduce operating expenses.

Direct competitors

Future Price to Earnings haleon.com (HLN)|KVUE (Kenvue Health) - Future Price to Earnings Multiple|Future Price to Earnings Verona Pharma PLC VRNA|Jyong Biotech (MENS) - Projected Price to Earnings Ratio|LGND: Projected Price to Earnings|Amneal - Market Cap to Future Earnings Ratio|PRGO: Forward P/E Multiple|Alvotech Corp - Future Price to Earnings Multiple|LQDA (Liquidia Corp) - Forward P/E Multiple|Projected Price to Earnings Ratio glpg.com GLPG|Future Price to Earnings ANI Pharmaceuticals, Inc. (ANIP)|MNKD (MannKind Corp) - Future Price to Earnings Multiple|Forward P/E Multiple AMPH (Amphastar Pharmaceuticals Inc)|PCRX (Pacira) - Price to Expected Earnings Ratio|SPRY - Future Price to Earnings|Future Price to Earnings Multiple TBPH (Theravance Biopharma)|AQST (aquestive.com) - Projected Price to Earnings|Price to Expected Earnings Ratio SCPH (scPharmaceuticals, Inc.)|Projected Price to Earnings TECX|Tonix Pharmaceuticals (TNXP) - Market Cap to Projected Earnings|Forward P/E Multiple SXTC|Forward P/E Multiple Eupraxia Pharma (EPRX)|Future Price to Earnings BioHarvest Sciences Inc. BHST|EXOZ - Projected Price to Earnings|ORMP: Projected Price to Earnings|Future Price to Earnings Multiple ENTX (enterabio.com)|MindWalk Therapeutics (HYFT) - Future Price to Earnings|Projected Price to Earnings Ratio abvcpharma.com (ABVC)|Future Price to Earnings Cumberland Pharma|Future Price to Earnings QNTM|Forward P/E Multiple FGEN|TELO (Telomir Pharma) - Future Price to Earnings Multiple|Forward P/E Multiple SNYR (Synergy CHC Corp)|Rallybio Corporation (RLYB) - Projected Price to Earnings Ratio|LEXX - Future Price to Earnings|PULM (Pulmatrix) - Price to Future Earnings Ratio|Pheton Holdings Ltd (PTHL) - Future Price to Earnings|Aptorum - Future Price to Earnings Multiple|Projected Price to Earnings LYRA|Projected Price to Earnings Impact BioMedical Inc (IBO)|Forward P/E Multiple TNFA|YCBD: Price to Expected Earnings Ratio|Future Price to Earnings PainReform PRFX|altamiratherapeutics.com (CYTO) - Projected Price to Earnings Ratio|LIPO: Projected Price to Earnings|OPTN (optinose.com) - Price to Future Earnings Ratio|PIRS: Forward P/E Multiple|PROC - Market Cap to Projected Earnings|PTPI (Petros Pharma) - Forward P/E Multiple|Future Price to Earnings QLI|Forward P/E Multiple SLRN|Market Cap to Future Earnings Ratio TFFP